アルツハイマー病の病理を標的とする:多標的リガンドとしてテトラロンとチオクロマノンベースのベンジルピリジニウム誘導体

Anjali Sobha¹, Lekshmy Krishnan², Shareef Shaik³

¹Chemical Sciences and Technology Division, CSIR-National Institute for Interdisciplinary Science and Technology (CSIR-NIIST), Thiruvananthapuram 695 019, Kerala, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201 002, India.

Bioorganic & medicinal chemistry

|August 29, 2025

まとめ

研究者は,アルツハイマー病 (AD) と戦うために新しいベンジルピリジニウム塩を開発しました. 化合物4eは多標的薬として有望で炎症や酸化ストレスを軽減し脳細胞を保護します

科学分野:

薬剤化学
神経科学
薬理学について

背景:

アルツハイマー病 (AD) は進行を止める効果的な治療法がない.
複数の病理的な経路がADに寄与し,マルチターゲットのアプローチを必要とします.

研究の目的:

テトラロン/チオクロマノンベースのベンジルピリジニウム塩の設計と合成.
これらの化合物をAD治療のための多標的リガンド (MTDL) として評価する.

主な方法:

ベンジルピリジニウム塩 (4a-4s) の合成
コリンエステラス (AChE) とモノアミン酸化酵素 (MAO- B) 抑制に対するインビトロスクリーニング
抗神経炎症効果 (サイトカイン,COX-2,NF-κB) の評価
Aβ1−42に対するSH-SY5Y細胞における活性酸素種 (ROS) スキャビングと神経保護の評価.

主要な成果:

化合物4eと4gは強力なAChEとMAO- B阻害剤でした.
4eと4gは,炎症を誘発するサイトカインを減少させ,COX- 2/ NF- kB経路を阻害した.
化合物4eは,有意なROSスキャビングを示し,Aβ1- 42毒性からSH- SY5Y細胞を保護しました.
神経細胞のミトコンドリア機能障害とアポトーシスが弱まった.

結論:

化合物4eはADの病理学に関連した多標的活性を示しています.
4eは,アルツハイマー病の治療のための有望なMTDLの可能性があることを示しています.

キーワード:

AChE 阻害アルツハイマー病 (AD)アミロイドβ MAO-B 抑制ミトコンドリア機能障害マルチターゲットのリガンド (MTDL)神経炎症 ROSのスキャビング能力

さらに関連する動画

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on ¹⁸F-AV-1451

Published on: April 18, 2025

348

06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

12.0K

関連する概念動画

01:22

Alzheimer's Disease: Treatment

260

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

260

01:26

Alzheimer's Disease: Overview

666

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

666

01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

2.6K

Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...

2.6K

01:24

Parkinson's Disease: Treatment

376

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

376

01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

645

Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...

645

01:19

Ligand-gated Ion Channels

12.7K

Ligand-gated ion channels are transmembrane proteins with a channel for ions to pass through and a binding site for a ligand. The channel opens only when a ligand attaches to the binding site.
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that...